AD-GITR-LSOL

AD-GITR-LSOL appears to be a research or investigational drug, likely an agonistic agent targeting the glucocorticoid-induced tumor necrosis factor receptor (GITR), which is a co-stimulatory molecule on T cells. Drugs targeting GITR are being explored as potential immuno-oncology therapies to activate anti-tumor immune responses by modulating regulatory and effector T cell activity. The suffix “LSOL” could indicate a specific formulation or construct, such as a long-acting solution or engineered antibody format. As of this time, there is no publicly available evidence of clinical data or development status specifically for “AD-GITR-LSOL.” However, GITR agonists in general are under investigation for various advanced solid tumors and hematologic malignancies.

Brand names

AD-GITR-LSOL

Other names

AD-GITR-LSOL